These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
127 related items for PubMed ID: 8233642
1. [Quantitative viremia and p24 antigenemia in short-term follow-up of the treatment with zidovudine in twenty HIV infected patients]. Tamalet C, Puel J, Fleury H, Ferchal F, Agut H, Brun-Vezinet F, Botti G, Rouzioux C. Pathol Biol (Paris); 1993 Apr; 41(4):399-403. PubMed ID: 8233642 [Abstract] [Full Text] [Related]
2. The prognostic value of plasma viremia in HIV-infected patients under AZT treatment: a two-year follow-up study. Ruffault A, Michelet C, Jacquelinet C, Guist'hau O, Genetet N, Bariou C, Colimon R, Cartier F. J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul 01; 9(3):243-8. PubMed ID: 7788423 [Abstract] [Full Text] [Related]
3. Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects. Mulder JW, Lange JM, de Wolf F, Houweling JT, Bakker M, Coutinho RA, Goudsmit J. Neth J Med; 1990 Aug 01; 37(1-2):4-10. PubMed ID: 2120599 [Abstract] [Full Text] [Related]
4. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection. Relimpio F, Rey C, Pineda JA, Leal M, Caruz A, Sánchez-Quijano A, Lissen E. Antivir Ther; 1997 Apr 01; 2(2):99-104. PubMed ID: 11322281 [Abstract] [Full Text] [Related]
5. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial. Chaisson RE, Leuther MD, Allain JP, Nusinoff-Lehrman S, Boone GS, Feigal D, Volberding P. Arch Intern Med; 1988 Oct 01; 148(10):2151-3. PubMed ID: 3263098 [Abstract] [Full Text] [Related]
6. [Quantification of the levels of p24 antigen and antibodies in human immunodeficiency virus infection]. García F, Quirós E, Bernal MC, Alados JC, González MI, Maroto MC. Enferm Infecc Microbiol Clin; 1992 Feb 01; 10(2):75-8. PubMed ID: 1643142 [Abstract] [Full Text] [Related]
12. Acute decrease in HIV-1 viral load after initiation of zidovudine therapy: implications for interrupting vertical transmission. Jackson JB. Pediatr AIDS HIV Infect; 1995 Dec 01; 6(6):358-9. PubMed ID: 11361462 [Abstract] [Full Text] [Related]
13. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. Godfried MH, van der Poll T, Mulder JW, Weverling GJ, Endert E, Lange JM, Sauerwein HP. J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec 15; 10(5):531-9. PubMed ID: 8548332 [Abstract] [Full Text] [Related]